原文摘录：See all DONs related to this event Read more about Ebola disease Situation at a glance Since the publication of the previous Disease Outbreak News on 23 October 2026, the Bundibugyo virus disease (BVD) outbreak has expanded geographically in the Democrati … item/2026-DON625
原文摘录：See all DONs related to this event Read more about Yellow fever Situation at a glance Yellow fever transmission continues in the WHO African Region, with recent outbreak activity concentrated in parts of West Africa. … item/2026-DON624
原文摘录：Rivaroxaban Viatris (previously Rivaroxaban Mylan) RSS Authorised This medicine is authorised for use in the European Union rivaroxaban Medicine Human Authorised Application under evaluation CHMP opinion European Commission decision Overview Rivaroxaban M … 21 MB - DOCX) First published: 04/06/2025 View This page was last updated on 06/11/2026
原文摘录：Yorvipath RSS Authorised This medicine is authorised for use in the European Union palopegteriparatide Medicine Human Authorised Application under evaluation CHMP opinion European Commission decision Overview Yorvipath is a hormone replacement medicine fo … 37 KB - PDF) First published: 15/09/2023 View News on Yorvipath Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023 15/09/2023 More information on Yorvipath EU/3/20/2350 - orphan designation for treatment of hypoparathyroidism EMA/PE/0000241327 - paediatric investigation plan A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide) - post-authorisation study A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding - post-authorisation study This page was last updated on 06/11/2026
原文摘录：Aldurazyme RSS Authorised This medicine is authorised for use in the European Union laronidase Medicine Human Authorised Application under evaluation CHMP opinion European Commission decision Overview This is a summary of the European public assessment re … This page was last updated on 06/11/2026
原文摘录：Bylvay RSS Authorised This medicine is authorised for use in the European Union odevixibat Medicine Human Authorised Application under evaluation CHMP opinion European Commission decision Overview Bylvay is a medicine for treating patients from the age of … More information on Bylvay EU/3/12/1028 - orphan designation for treatment of progressive familial intrahepatic cholestasis EU/3/12/1040 - orphan designation for treatment of Alagille syndrome EMEA-002054-PIP01-16-M03 - paediatric investigation plan EMA/PE/0000240317 - paediatric investigation plan Bylvay - withdrawal of application for variation to marketing authorisation Registry to Document Treatment Effectiveness, Safety, Including Prospective Long-term Outcomes in Participants with Progressive Familial Intrahepatic Cholestasis (PFIC) who take Odevixibat (Bylvay) - post-authorisation study Prospective Registry-Based Study Evaluating the Effectiveness and Safety of Odevixibat in Participants With Alagille Syndrome (ALGS) - post-authorisation study Prospective Registry-Based Study of the Long-Term Safety of Odevixibat in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) - post-authorisation study This page was last updated on 06/11/2026
原文摘录：Entyvio RSS Authorised This medicine is authorised for use in the European Union vedolizumab Medicine Human Authorised Application under evaluation CHMP opinion European Commission decision Overview Entyvio is a medicine used to treat adult patients with … 73 KB - PDF) First published: 21/03/2014 Last updated: 21/03/2014 View News on Entyvio Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021 17/12/2021 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2020 28/02/2020 European Medicines Agency recommends 39 medicines for human use for marketing authorisation in first half of 2014 10/07/2014 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 March 2014 21/03/2014 European Medicines Agency recommends approval of a locally targeted treatment for ulcerative colitis and Crohn's disease 21/03/2014 More information on Entyvio EMEA-000645-PIP03-18 - paediatric investigation plan EMEA-000645-PIP01-09-M09 - paediatric investigation plan EMEA-000645-PIP04-20-M02 - paediatric investigation plan Vedolizumab-4081: Infection Outcomes among Advanced Therapy-naive Older Adult US Patients With UC/CD Initiating ENTYVIO, TNF-alpha Inhibitors, or Ustekinumab: A Retrospective Observational Matched-Cohort Study Using Medicare Claims Data, 2016-2025 - post-authorisation study Vedolizumab-5001: Organization of Teratology Information Specialists (OTIS) Vedolizumab Pregnancy Exposure Registry - post-authorisation study Vedolizumab-5056: Clinical Effectiveness of Vedolizumab Used in Frames of Drug Program for Crohn’s Disease Treatment in Poland – Prospective, Observational Study Considering Fatigue and Other Patient-reported-outcomes (PROs) (POLONEZ II) - post-authorisation study Comparative Effectiveness of Tofacitinib Versus Ustekinumab and Vedolizumab among Ulcerative Colitis Patients With Prior Anti- Tumor Necrosis Factor (TNF) Failure - post-authorisation study Topics Medicines This page was last updated on 06/11/2026
原文摘录：Elaprase RSS Authorised This medicine is authorised for use in the European Union idursulfase Medicine Human Authorised Application under evaluation CHMP opinion European Commission decision Overview This is a summary of the European public assessment rep … This page was last updated on 06/11/2026
原文摘录：The purpose of this 1-year open-label extension study is to characterize the longer-term safety and tolerability of DDY391 and to assess the durability of clinical response in participants with Psoriatic Arthritis (PsA) who have completed treatment in the
原文摘录：Non-State actors information and engagement session 7 October 2026 Amid growing mistrust in science and widespread health misinformation, the WHO Civil Society Commission and the WHO Chief Scientist’s Office held an information session for non-State actor … int
原文摘录：Dr Geetha Krishnan Gopalakrishna Pillai of WHO Global Centre for Traditional Medicine, delivering his keynote at FoodMed 2026 Conference The FoodMed Conference returned for its second edition on 5–6 November 2026, bringing together international experts,
原文摘录：On Monday, 9 November, health takes centre stage as the thirty-first session of the Conference of the Parties (COP31) to the UN Framework Convention on Climate Change (UNFCCC) opens with a dedicated Health Day. … ATACH and AIR give countries the means to do that, during COP31 and beyond
原文摘录：One in four adolescents worldwide reported not getting at least 60 minutes of physical activity on any day in the previous week. … Stand with science”, the theme of World Health Day 2026, marks a year-long campaign to highlight science as the foundation for protecting health and well-being worldwide
关注理由：这条内分泌与代谢资料适合作为深入阅读入口，尤其要关注研究方法与结论是否匹配。
WHO候选疫苗优先技术咨询小组基于现有临床前和早期临床证据，建议将牛津大学与印度血清研究所的ChAdOx1及Moderna的mRNA-1469加入刚果（金）Tumaini试验，系针对Bundibugyo病毒的疫苗首次在疫情期间接受临床评估，待国家批准后入组。
关注理由：针对Bundibugyo病毒的候选疫苗首次在疫情期间进入临床评估，Tumaini多疫苗试验与治疗研究并行推进，结果时间表明确，可跟踪疫情期间疫苗评价模式的验证进展。
原文摘录：WHO / Monika Mey Local health workers in Cambodia are trained in surveillance techniques, including stool examination using Kato-Katz, to detect schistosomiasis eggs, identify potential hotspots and support early detection and treatment. … int Related Global report on neglected tropical diseases 2026 Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021–2030 WHO's work on neglected tropical diseases More WHO Global Neglected Tropical Diseases Programme
关注理由：关于感染病学的这条内容有明确出处，主要发现和适用人群可在原文中继续核查。
原文摘录：Six proven climate and health measures could save 1.6 million lives a year while delivering trillions of dollars in economic and fiscal gains, according to a new World Health Organization (WHO) report released today.
关注理由：这条医学资料适合作为深入阅读入口，尤其要关注研究方法与结论是否匹配。
原文摘录：Truqap - withdrawal of application for variation to marketing authorisation Application withdrawn The application for a change to this medicine's authorisation has been withdrawn capivasertib Post-authorisation Human Overview AstraZeneca AB withdrew its a … News on Truqap Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026 16/10/2026 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024 26/04/2024 More information on Truqap Truqap This page was last updated on 03/11/2026
关注理由：这篇临床试验内容涉及随机对照研究，阅读重点可以放在研究分组、主要终点和随访结果上。
原文摘录：See all DONs related to this event Situation at a glance On 20 October 2026, the National IHR Focal Point (NFP) of France notified WHO regarding the first documented human infection with Shamonda virus (SHAV). … item/2026-DON623
关注理由：这篇神经内科资料可用于了解领域进展，研究设计、结果和局限性值得一起阅读。
原文摘录：Image credit: © tadamichi | stock.adobe.com Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26 - 29 October 2026 30 October 2026 PRAC starts review of depression and anxiety medicine Deanxit and a safety signal related to hu … eu All other enquiries please submit your request via the online form Follow us on Bluesky Related medicine information Flupentixol/melitracen-containing medicinal products - referral Topics Pharmacovigilance
关注理由：如果关注精神医学，这篇内容值得阅读其研究对象、方法设计和主要发现。
原文摘录：This recall involves implementing additional recommendations on the use of the StatStrip Glucose Hospital Meter System while awaiting a software update. … 10/20/2026 The FDA issued a communication notifying the public of a Class I Recall
关注理由：这篇内分泌与代谢内容涉及具体研究方向，原文中的样本、结局和限制有助于理解其价值。
原文摘录：Ibrance - withdrawal of application for variation to marketing authorisation Application withdrawn The application for a change to this medicine's authorisation has been withdrawn palbociclib Post-authorisation Human Overview Pfizer Europe MA EEIG withdre … News on Ibrance Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026 16/10/2026 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2016 (corrected) 21/09/2016 New treatment for breast cancer 16/09/2016 More information on Ibrance Ibrance This page was last updated on 28/10/2026
关注理由：这篇肿瘤学内容涉及临床试验，适合了解研究正在回答什么问题，试验阶段和主要终点需以原文为准。
原文摘录：See all DONs related to this event Read more about Ebola disease Situation at a glance Since the publication of the previous Disease Outbreak News on 8 October 2026, the Bundibugyo virus disease (BVD) outbreak has expanded geographically in the Democratic … item/2026-DON622
关注理由：这条诊断与检测临床试验动态值得跟踪，后续可结合原文核对试验进度、研究设计与结果披露情况。
原文摘录：Image credit: © peterschreiber.media | stock.adobe.com AMA and EMA issue joint guidance on Ebola vaccine development 23 October 2026 Clinical trial requirements defined for rapid development of Bundibugyo virus vaccines News Human Clinical trials Research … eu All other enquiries Please submit your request via the online form
关注理由：这条儿科学资料涉及临床试验，入组条件、对照设置和研究阶段可以帮助判断结果适用于哪些人群。
原文摘录：Summary Company Announcement Date: October 21, 2026 FDA Publish Date: October 21, 2026 Product Type: Animal & Veterinary Drugs Reason for Announcement: Recall Reason Description Potential Potency Issues Company Name: Wedgewood Pharmacy, LLC. … Company Contact Information Consumers: Sedgwick 866-562-5931
原文摘录：Driving frequently exposes individuals to conditions triggering acute stress, but its effects on drivers' visual behaviour remain insufficiently understood. … They also indicate that multimodal context-aware validation is needed for translation into real-time driver state monitoring and safety-relevant assistance applications
原文摘录：Kaftrio - withdrawal of application for variation to marketing authorisation Application withdrawn The application for a change to this medicine's authorisation has been withdrawn ivacaftor / tezacaftor / elexacaftor Post-authorisation Human Overview Vert … News on Kaftrio Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2026 18/09/2026 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2025 28/02/2025 Combination of cystic fibrosis medicines to treat patients with rare mutations 28/02/2025 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023 15/09/2023 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021 12/11/2021 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 March 2021 26/03/2021 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2020 26/06/2020 New medicine for cystic fibrosis patients 26/06/2020 More information on Kaftrio Kaftrio This page was last updated on 20/10/2026
关注理由：如果关注儿科学，这条临床试验动态可用于了解研究设计，主要终点和试验阶段建议查看原文。
原文摘录：Disease Outbreak News Middle East respiratory syndrome coronavirus - Kingdom of Saudi Arabia 15 October 2026 See all DONs related to this event Situation at a glance Between 1 January and 5 October 2026, the Kingdom of Saudi Arabia reported eight laborato … int/emergencies/disease-outbreak-news/item/2026-DON618 See all DONs related to this event
原文摘录：Image credit: © Chinnapong | stock.adobe.com EMA recommends authorisation of Rasonque for metastatic pancreatic cancer 15 October 2026 Phased review fast tracks assessment of medicine addressing unmet medical need News Human Innovation Medicines EMA’s hum … eu All other enquiries Please submit your request via the online form Follow us on Bluesky Related medicine information Rasonque
关注理由：这条肿瘤学内容涉及相关临床或研究问题，建议查看原文中的方法与适用范围。
原文摘录：Disease Outbreak News Pneumonia of undetermined etiology - Russian Federation 10 October 2026 See all DONs related to this event Situation at a glance On 2 October 2026, WHO became aware through media reports of the death of an employee of the Irkutsk Ant … item/2026-DON620 See all DONs related to this event
关注理由：这条感染病学资料适合作为深入阅读入口，尤其要关注研究方法与结论是否匹配。
原文摘录：Kalydeco - withdrawal of application for variation to marketing authorisation Application withdrawn The application for a change to this medicine's authorisation has been withdrawn ivacaftor Post-authorisation Human Overview Vertex Pharmaceuticals (Irelan … News on Kalydeco Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2026 18/09/2026 Combination of cystic fibrosis medicines to treat patients with rare mutations 28/02/2025 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024 23/02/2024 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023 15/09/2023 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021 12/11/2021 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 March 2021 26/03/2021 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020 18/09/2020 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020 24/07/2020 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020 30/04/2020 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2019 18/10/2019 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018 19/10/2018 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018 27/07/2018 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 September 2015 25/09/2015 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 June 2014 27/06/2014 More information on Kalydeco Kalydeco This page was last updated on 09/10/2026
关注理由：这条儿科学临床试验动态值得跟踪，后续可结合原文核对试验进度、研究设计与结果披露情况。
原文摘录：See all DONs related to this event Read more about Ebola disease Situation at a glance On 5 October 2026, WHO was informed about a laboratory-confirmed imported case of Bundibugyo virus disease (BVD) in Kenya with travel history from the Democratic Republ … item/2026-DON619
关注理由：这条诊断与检测临床试验动态值得跟踪，后续可结合原文核对试验进度、研究设计与结果披露情况。
原文摘录：Pulmonary blood volumes (PBV), currently not assessed by computed tomography pulmonary angiography (CTPA), could provide additional information to routine investigations performed for chronic thromboembolic pulmonary hypertension (CTEPH). … Utilizing CTPA-derived PBV post-PEA to identify patients without residual PH can potentially reduce the need for routine postoperative right heart catheterization
原文摘录：See all DONs related to this event Read more about Ebola disease Situation at a glance Since the last Disease Outbreak News was published on 11 September 2026, the Bundibugyo virus outbreak in the Democratic Republic of the Congo has expanded further, wit … item/2026-DON621
关注理由：关于诊断与检测的临床试验有新资料可供查看，主要终点、入组标准和研究阶段是几个重要阅读点。